Press Release Highlights
First half 2025 revenue of $1.4 million, a 33% increase over same period of 2024
Announced an expanded set of instrument acquisition options in response to current capital purchasing challenges
Product development programs remain on track - ProteusT™ platform, v4 Sequencing Kit, and v3 Library Preparation Kit Announced two new R&D initiatives that will further accelerate breadth of applications addressable with our core technology
Raised gross $50 million in capital through a registered direct offering and updated cash runway into the second quarter of 2028
Announced planned Investor and Analyst Day in New York City in November 2025
First half 2025 revenue of $1.4 million, a 33% increase over same period of 2024
Announced an expanded set of instrument acquisition options in response to current capital purchasing challenges
Product development programs remain on track - ProteusT™ platform, v4 Sequencing Kit, and v3 Library Preparation Kit Announced two new R&D initiatives that will further accelerate breadth of applications addressable with our core technology
Raised gross $50 million in capital through a registered direct offering and updated cash runway into the second quarter of 2028
Announced planned Investor and Analyst Day in New York City in November 2025